ES2721286T3 - Derivados heterociclialquinos y su uso como moduladores de los receptores mGluR5 - Google Patents

Derivados heterociclialquinos y su uso como moduladores de los receptores mGluR5 Download PDF

Info

Publication number
ES2721286T3
ES2721286T3 ES15822958T ES15822958T ES2721286T3 ES 2721286 T3 ES2721286 T3 ES 2721286T3 ES 15822958 T ES15822958 T ES 15822958T ES 15822958 T ES15822958 T ES 15822958T ES 2721286 T3 ES2721286 T3 ES 2721286T3
Authority
ES
Spain
Prior art keywords
group
optionally substituted
alkyl
modulators
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15822958T
Other languages
English (en)
Inventor
Carlo Riva
Patrizia Angelico
Elena Poggessi
Toma Carlo De
Davide Graziani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati Ireland Ltd
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Application granted granted Critical
Publication of ES2721286T3 publication Critical patent/ES2721286T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula I **Fórmula** o un enantiómero, diastereómero o una sal farmacéuticamente aceptable del mismo en el que: R1 es un grupo CO opcionalmente sustituido por uno o más grupos o sustituyentes R2; R2 está ausente o es un grupo heterocíclico C1-C9 mono o bicíclico opcionalmente sustituido que contiene de 1 a 3 heteroátomos seleccionados entre nitrógeno, oxígeno y azufre, un grupo arilo C6-C14 mono, bi o tricíclico opcionalmente sustituido, o un grupo opcionalmente sustituido escogido entre alquilo, cicloalquilo, alcoxi, cicloalcoxi, ariloxi, heteroariloxi, alquiltio, amino, N-alquilamino, N,N-dialquilamino o N-alquil-N-alcoxiamino; R3 es un grupo fenilo o piridilo opcionalmente sustituido, seleccionándose dichos sustituyentes opcionales de un grupo haluro o de un grupo alquilo C1-C10, y siendo n igual a 1.
ES15822958T 2014-12-29 2015-12-29 Derivados heterociclialquinos y su uso como moduladores de los receptores mGluR5 Active ES2721286T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462097482P 2014-12-29 2014-12-29
PCT/EP2015/081337 WO2016107865A1 (en) 2014-12-29 2015-12-29 Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors

Publications (1)

Publication Number Publication Date
ES2721286T3 true ES2721286T3 (es) 2019-07-30

Family

ID=55080108

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15822958T Active ES2721286T3 (es) 2014-12-29 2015-12-29 Derivados heterociclialquinos y su uso como moduladores de los receptores mGluR5

Country Status (16)

Country Link
US (2) US9593127B2 (es)
EP (1) EP3240792B1 (es)
JP (1) JP6691127B2 (es)
KR (1) KR20170100656A (es)
CN (1) CN107406461B (es)
AU (1) AU2015373392B2 (es)
BR (1) BR112017014226A2 (es)
CA (1) CA2972668A1 (es)
EA (1) EA035237B1 (es)
ES (1) ES2721286T3 (es)
IL (1) IL253227A0 (es)
MX (1) MX2017008639A (es)
PH (1) PH12017501209A1 (es)
SG (1) SG11201705355VA (es)
WO (1) WO2016107865A1 (es)
ZA (1) ZA201704416B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL202623B1 (pl) 2000-06-28 2009-07-31 Smithkline Beecham Plc Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
EP2414340A1 (en) * 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
TW201116532A (en) * 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
KR101862626B1 (ko) * 2010-07-09 2018-05-31 레코르다티 아일랜드 리미티드 Mglu5 대항체로서의 신 스피로헤테로사이클릭 화합물
CA2806103A1 (en) * 2010-08-31 2012-03-08 Vanderbilt University Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mglur5 receptors

Also Published As

Publication number Publication date
KR20170100656A (ko) 2017-09-04
PH12017501209A1 (en) 2017-10-18
ZA201704416B (en) 2019-06-26
AU2015373392A1 (en) 2017-08-17
US20160185798A1 (en) 2016-06-30
EP3240792B1 (en) 2019-01-23
EA201791439A1 (ru) 2018-02-28
MX2017008639A (es) 2018-05-28
US9889121B2 (en) 2018-02-13
IL253227A0 (en) 2017-08-31
WO2016107865A1 (en) 2016-07-07
EA035237B1 (ru) 2020-05-19
CA2972668A1 (en) 2016-07-07
NZ734071A (en) 2018-08-31
CN107406461B (zh) 2020-03-13
US9593127B2 (en) 2017-03-14
JP2018500371A (ja) 2018-01-11
CN107406461A (zh) 2017-11-28
SG11201705355VA (en) 2017-08-30
EP3240792A1 (en) 2017-11-08
JP6691127B2 (ja) 2020-04-28
US20170182011A1 (en) 2017-06-29
BR112017014226A2 (pt) 2018-03-06
AU2015373392B2 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
PE20181024A1 (es) Derivados de ciclohexano sustituido con amido
PE20180117A1 (es) Inhibidores de indolamina-2,3-dioxigenasa para el tratamiento de cancer
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR106798A1 (es) Inhibidores pirazol de acc y usos de los mismos
SV2016005328A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
NZ732649A (en) Picolinamides and related compounds
ES2659397T3 (es) 2-azabicíclicos sustituidos y su uso como moduladores receptores de orexinas
AR099995A1 (es) Piridilamidinas fungicidas
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
ES2684517T3 (es) Compuestos de heterociclilo como inhibidores de MEK
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
UY36838A (es) Compuestos heterocíclicos moduladores de la señalización de tnf alfa y composiciones farmacéuticas que los contienen
DOP2012000318A (es) Compuestos heterociclicos fusionados
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
ES2635318T3 (es) Moduladores P2X7
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
CL2021000296A1 (es) Inhibidores tipo indol y azaindol de enzimas pad.
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CO6362013A2 (es) Derivados de rifamicina
AR103414A1 (es) Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3
AR093503A1 (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina
CL2020002588A1 (es) Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016)